The latest study says that heart disease risk begins in the womb if a mother had suffered complications during her pregnancy. According to researchers from the University of Cambridge, heart disease is one of the biggest and gravest reasons behind mortality. It is already accepted and proven that there is an interconnection between the human gene and life risk factors such as smoking, inactive lifestyle, and obesity. A study published in PLOS Biology Journal has mentioned that evidence of the gene-environment interaction before birth is already discovered.
In the study of human siblings, it was shown that children who were born to an obese mother may have a higher risk of heart disease. However, the scientists had resolved the issue with an experiment called bariatric surgery. They found siblings who born to the same mother after bariatric surgery had comparatively fewer chances of risk if heart disease. The latest study shows that children born during chronic hypoxia complicated pregnancy have exhibited an increased risk of cardiovascular disease which includes stiffer blood vessels and high blood pressure. Chronic hypoxia of lower oxygen levels in the baby within the womb is most severe conditions that typically lead to complicated pregnancy in human. The condition often reflects with issues in placenta, and it can cause by gestational diabetes or maternal smoking.
For this research, lead author Dino Giussani took a pregnant sheep for the experiment. He tried to present how the maternal treatment with the antioxidant vitamin C protects a child form evolving risk of heart disease during a complicated pregnancy. The research presents the affirmations that a prenatal impact on later heart disease in the child is certainly possible. Meanwhile, the study also shows the possibility to safeguard against heart by including preventative medicine into the womb. Researchers said that vitamin C is protective but very strong antioxidant, so they will focus to discover a strong optional antioxidant in the future for therapies that could exhibit more effective results in clinical trials.